Validated biomarker panels, MRM PK assays, and Olink proteomics for therapeutic development programs.
CellCarta’s neurosciences biomarker services brings specialized expertise in the proteomic analysis of biomarkers relevant to neurological disorders.
Having worked with various biopharmaceutical partners and non-profit organizations such as the Michael J. Fox Foundation, we can apply our experience to support discovery and clinical neuroscience programs.
Don’t see your indication? Contact us about custom solutions.
Contact Us
Validated MRM panels and APOE isotyping to measure NPTX2, VGF, SCG2, CgA, FABP3, and more.
Biomarker discovery and mass spectrometry (MS)-based panel development for Parkinson's programs.
Custom biomarker panels and biotherapeutic characterization for Huntington’s research.
Protein biomarker quantification and assay development for CNS programs in schizophrenia.
Flow cytometry for T cell subset tracking, cytokine quantification, and biomarker assessment.
We can implement off-the-shelf (OTS) panels for rapid CNS biomarker assessment, or develop and validate custom panels tailored to your study’s specifications, enabling disease monitoring, patient stratification, and therapeutic assessment.
Biomarker panels can be designed for exploratory, primary, and secondary endpoints, and may accommodate a range of relevant clinical sample types, including brain tissue, cerebrospinal fluid (CSF), and plasma.
We have developed and validated various analytical workflows for a range of relevant matrices, including CSF, brain tissue, and plasma, supporting both exploratory and regulated CNS programs.
This includes a targeted MS-based panel that measures 142 Parkinson’s-related biomarkers.
Whether your study requires relative or absolute quantification of biologics and biomarkers, we can implement MS, nCounter, Olink®, and MSD®, for precise, accurate measurements.
CellCarta’s integrated sample logistics and global laboratory network support clinical trial specimen collection, processing, and analysis at scale, including for CNS studies requiring CSF sample handling.
We can handle your study’s operational performance with ease, allowing your team to focus on the science at hand.
We can implement off-the-shelf (OTS) panels for rapid CNS biomarker assessment, or develop and validate custom panels tailored to your study’s specifications, enabling disease monitoring, patient stratification, and therapeutic assessment.
Biomarker panels can be designed for exploratory, primary, and secondary endpoints, and may accommodate a range of relevant clinical sample types, including brain tissue, cerebrospinal fluid (CSF), and plasma.
We have developed and validated various analytical workflows for a range of relevant matrices, including CSF, brain tissue, and plasma, supporting both exploratory and regulated CNS programs.
This includes a targeted MS-based panel that measures 142 Parkinson’s-related biomarkers.
Whether your study requires relative or absolute quantification of biologics and biomarkers, we can implement MS, nCounter, Olink®, and MSD®, for precise, accurate measurements.
CellCarta’s integrated sample logistics and global laboratory network support clinical trial specimen collection, processing, and analysis at scale, including for CNS studies requiring CSF sample handling.
We can handle your study’s operational performance with ease, allowing your team to focus on the science at hand.
CellCarta uses a platform agnostic approach to deliver relative and absolute quantification of biomarkers across clinical matrices.
Olink PEA technology enables high-multiplex protein biomarker quantification from minimal sample volume. Neuroscience-specific panels include the Olink Neurology and Neuro Exploratory panel.
MS-based assays support targeted and untargeted quantification of protein biomarkers and biotherapeutics in CSF, plasma, and brain tissue. CellCarta's MS workflows are applied across exploratory and regulated CNS studies.
MSD technology supports relative and absolute quantification of protein biomarkers in relevant biological matrices. MSD enables multiplex immunoassay applications relevant to CNS inflammation and neurodegeneration research.
Publications
CellCarta is proud to have supported a number of studies that aim to advance the understanding and prognosis for various neurological disorders. Our neuroscience biomarker services are highlighted in several journals, including Science Translational Medicine.
News
CellCarta has formed a strategic partnership with Tivenix to support the development and commercialization of their innovative diagnostic platform for Alzheimer’s disease and other neurodegenerative diseases. This platform aims to offer a sensitive, specific, and minimally invasive blood test for early disease diagnosis and patient stratification.
Validated CNS biomarker expertise for precise, reliable clinical analysis.
Platform Agnostic Workflow
Custom Assay Development
Full Program Support
Complex Biomarker Expertise
Established Partnerships
CellCarta’s neurosciences biomarker services support biomarker and assay development across a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, Schizophrenia, and Multiple Sclerosis. Custom solutions are available for additional indications; contact the team to discuss your program's specific requirements.
CellCarta leverages several technology platforms: Olink Proximity Extension Assay (PEA) technology for high-multiplex protein biomarker quantification (including Neurology and Neuro Exploratory panels), Meso Scale Discovery (MSD) for relative and absolute quantification in clinical matrices, MRM mass spectrometry for absolute quantification of biotherapeutics in brain tissue, CSF, and plasma, and NanoString nCounter for genomic analysis.
CellCarta’s neurosciences biomarker services supports biomarker discovery, protein quantification, and PK analysis across exploratory, translational, and regulated study phases, with integrated sample logistics and global facilities to support clinical trial needs.
